BRL Medicine’s BRL-101 Meets Primary Endpoint in Pivotal Trial for Transfusion-Dependent β-Thalassemia
BRL Medicine’s gene-edited stem cell therapy BRL-101 has met the prespecified primary efficacy endpoint in a pivotal Chinese study for transfusion-dependent β-thalassemia, with all 30 treated patients achieving transfusion independence and the…